BFM
SIOX

Boothbay Fund Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Boothbay Fund Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$13.1K – 2657
2022
Q4 		$13.1K Hold
30,000
– – ﹤0.01% 1934
2022
Q3 		$8K Hold
30,000
– – ﹤0.01% 2182
2022
Q2 		$11K Buy
+30,000
New +$12.4K ﹤0.01% 2195
2020
Q4 		– Sell
-38,028
Closed -$176K – 1487
2020
Q3 		$176K Sell
38,028
-772
-2% -$2.55K 0.01% 957
2020
Q2 		$109K Hold
38,800
– – 0.01% 875
2020
Q1 		$95K Hold
38,800
– – 0.01% 730
2019
Q4 		$199K Sell
38,800
-7,189
-16% -$39.9K 0.02% 711
2019
Q3 		$297K Hold
45,989
– – 0.03% 578
2019
Q2 		$287K Buy
45,989
+2,354
+5% +$17.9K 0.03% 537
2019
Q1 		$464K Buy
43,635
+17,681
+68% +$176K 0.05% 402
2018
Q4 		$207K Buy
25,954
+23,716
+1,060% +$342K 0.03% 487
2018
Q3 		$43K Hold
2,238
– – ﹤0.01% 747
2018
Q2 		$40K Buy
+2,238
New +$33K ﹤0.01% 713

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Boothbay Fund Management's SIOX Position: Q1 2023 in Review

Boothbay Fund Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 30,000 shares — an estimated $13.1K sold.

Boothbay Fund Management first reported a position in SIOX in Q2 2018 and held it in 13 quarters. The position peaked at $464K in Q1 2019. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • Boothbay Fund Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 30,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $13.1K.
  • Boothbay Fund Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 13 quarters.
  • Boothbay Fund Management's Sio Gene Therapies Inc. Common Stock position peaked at $464K in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.